Terlipressin and hepatorenal syndrome: What is important for nephrologists and hepatologists

World Journal of Gastroenterology

Volumn 16, Issue 41, 2010, Pages 5139-5147

  Magan, Ahmed A ^a   Khalil, Atif A ^b   Ahmed, Mohamed H ^c  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Heptorenal syndrome; Kidney; Liver; Terlipressin

Indexed keywords

ALBUMIN; NITRIC OXIDE; NORADRENALIN; PLACEBO; TERLIPRESSIN;

ADRENERGIC SYSTEM; EDITORIAL; HEART OUTPUT; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; NEPHROLOGIST; NONHUMAN; PATHOGENESIS; PORTAL HYPERTENSION; PRESSORECEPTOR REFLEX; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 78649409437     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i41.5139     Document Type: Editorial

References (79)

1. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176
2. Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1: 1066-1079
3. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8
4. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827
5. Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 1993; 73: 375-411
6. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002; 17: 882-888
7. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002; 97: 2046-2050
8. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64
9. Péron JM, Bureau C, Gonzalez L, Garcia-Ricard F, de Soyres O, Dupuis E, Alric L, Pourrat J, Vinel JP. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2005; 100: 2702-2707
10. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51: 576-584
11. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25: 880-885
12. Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-948
13. Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-875
14. Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W, Arroyo V, Rodés J. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41
15. Lenz K, Hörtnagl H, Druml W, Grimm G, Laggner A, Schneeweisz B, Kleinberger G. Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut 1989; 30: 90-96
16. Obritsch MD, Bestul DJ, Jung R, Fish DN, MacLaren R. The role of vasopressin in vasodilatory septic shock. Pharmacotherapy 2004; 24: 1050-1063
17. Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48
18. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14: 1363-1368
19. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-156
20. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-930
21. Papper S. Hepatorenal syndrome. Contrib Nephrol 1980; 23: 55-74
22. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; 271: 1121-1125
23. Epstein M, Berk DP, Hollenberg NK, Adams DF, Chalmers TC, Abrams HL, Merrill JP. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970; 49: 175-185
24. Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20: 362-369
25. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003; 38 Suppl 1: S54-S68
26. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478-491
27. Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999; 19: 397-410
28. Benoit JN, Womack WA, Hernandez L, Granger DN. Forward and backward flow mechanisms of portal hypertension. Relative contributions in the rat model of portal vein stenosis. Gastroenterology 1985; 89: 1092-1096
29. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87: 1120-1126
30. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-G57
31. Kim MY, Baik SK. [Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension] Korean J Gastroenterol 2009; 54: 143-148
32. Knotek M, Rogachev B, Schrier RW. Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis. Can J Gastroenterol 2000; 14 Suppl D: 112D-121D
33. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995; 22: 370-376
34. Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-541
35. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-666
36. Ros J, Clària J, Jiménez W, Bosch-Marcé M, Angeli P, Arroyo V, Rivera F, Rodés J. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995; 22: 915-920
37. Adams LB, Hibbs JB Jr, Taintor RR, Krahenbuhl JL. Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J Immunol 1990; 144: 2725-2729
38. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142
39. Stuehr DJ, Marletta MA. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA 1985; 82: 7738-7742
40. Zhou L, Zhu DY. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009; 20: 223-230
41. Ni J, McLoughlin RM, Brodovitch A, Moulin P, Brouckaert P, Casadei B, Feron O, Topley N, Balligand JL, Devuyst O. Nitric oxide synthase isoforms play distinct roles during acute peritonitis. Nephrol Dial Transplant 2010; 25: 86-96
42. Förstermann U, Boissel JP, Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12: 773-790
43. Togashi H, Sakuma I, Yoshioka M, Kobayashi T, Yasuda H, Kitabatake A, Saito H, Gross SS, Levi R. A central nervous system action of nitric oxide in blood pressure regulation. J Pharmacol Exp Ther 1992; 262: 343-347
44. Sakuma I, Togashi H, Yoshioka M, Saito H, Yanagida M, Tamura M, Kobayashi T, Yasuda H, Gross SS, Levi R. NGmethyl- L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. A role for nitric oxide in the central regulation of sympathetic tone? Circ Res 1992; 70: 607-611
45. el Karib AO, Sheng J, Betz AL, Malvin RL. The central effects of a nitric oxide synthase inhibitor (N omega-nitro-L-arginine) on blood pressure and plasma renin. Clin Exp Hypertens 1993; 15: 819-832
46. Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK, Di Silvio M, Wang SC, Nakayama DK, Simmons RL, Snyder SH, Billiar TR. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA 1993; 90: 3491-3495
47. Kobzik L, Bredt DS, Lowenstein CJ, Drazen J, Gaston B, Sugarbaker D, Stamler JS. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 1993; 9: 371-377
48. Pollock JS, Nakane M, Buttery LD, Martinez A, Springall D, Polak JM, Förstermann U, Murad F. Characterization and localization of endothelial nitric oxide synthase using specific monoclonal antibodies. Am J Physiol 1993; 265: C1379-C1387
49. Wu KK. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann N Y Acad Sci 2002; 962: 122-130
50. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-1157
51. Iwao T, Oho K, Sakai T, Tayama C, Sato M, Nakano R, Yamawaki M, Toyonaga A, Tanikawa K. Splanchnic and extrasplanchnic arterial hemodynamics in patients with cirrhosis. J Hepatol 1997; 27: 817-823
52. Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997; 17: 505-519
53. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38 Suppl 1: S69-S89
54. Peti-Peterdi J, Harris RC. Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol 2010; 21: 1093-1096
55. Kashani A, Landaverde C, Medici V, Rossaro L. Fluid retention in cirrhosis: pathophysiology and management. QJM 2008; 101: 71-85
56. Henriksen JH, Moller S. Liver cirrhosis and arterial hypertension. World J Gastroenterol 2006; 12: 678-685
57. Schrier RW. Renin-angiotensin in preascitic cirrhosis: evidence for primary peripheral arterial vasodilation. Gastroenterology 1998; 115: 489-491
58. Pereira RM, dos Santos RA, da Costa Dias FL, Teixeira MM, Simões e Silva AC. Renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol 2009; 15: 2579-2586
59. Vilas-Boas WW, Ribeiro-Oliveira A Jr, Ribeiro Rda C, Vieira RL, Almeida J, Nadu AP, Simões e Silva AC, Santos RA. Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients. World J Gastroenterol 2008; 14: 6824-6830
60. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148-155
61. Vilas-Boas WW, Ribeiro-Oliveira A Jr, Pereira RM, Ribeiro Rda C, Almeida J, Nadu AP, Simões e Silva AC, dos Santos RA. Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. World J Gastroenterol 2009; 15: 2512-2519
62. Li Y, Liu H, Gaskari SA, Tyberg JV, Lee SS. Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide. Am J Physiol Gastrointest Liver Physiol 2008; 295: G252-G259
63. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654
64. Hernández-Guerra M, García-Pagán JC, Bosch J. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol 2005; 39: S131-S137
65. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology 1990; 12: 481-485
66. Ruffolo RR Jr, Kopia GA. Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure. Am J Med 1986; 80: 67-72
67. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol 2006; 12: 837-842
68. Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med 1969; 280: 1367-1371
69. Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE. Recovery from hepatorenal syndrome after orthotopic liver transplantation. N Engl J Med 1973; 289: 1155-1159
70. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-570
71. Testro AG, Wongseelashote S, Angus PW, Gow PJ. Longterm outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 2008; 23: 1535-1540
72. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-1368
73. Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-1359
74. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53: 830-835
75. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505
76. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008; 103: 1689-1697
77. Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol 2010; Epub ahead of print
78. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006; 24: 935-944
79. Fabrizi F, Dixit V, Messa P, Martin P. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials. Int J Artif Organs 2009; 32: 133-140